Quick summary
Retatrutide is an investigational medicine being studied for obesity, type 2 diabetes and related conditions. As checked on 11 September 2026, it is not FDA approved. Promising trial results do not make products sold online as “retatrutide” an approved or reliable treatment.
What is retatrutide?
Retatrutide acts on three hormone receptors: GIP, GLP-1 and glucagon. This is why it is described as a triple agonist. The expression “GLP-3,” sometimes used online, is not its scientific drug class. Researchers are studying whether this combination can improve weight and glucose outcomes with an acceptable safety profile.
What does the research show?
A randomized, placebo-controlled phase 2 obesity trial published in the New England Journal of Medicine in 2023 enrolled 338 adults and reported substantial weight loss. This was a research study with defined eligibility, follow-up and safety monitoring. It was not evidence that everyone would achieve the same result.
Development has since advanced to phase 3. Lilly’s July 2026 update describes results from several studies, including TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, TRIUMPH-4 and TRANSCEND-T2D-1. The populations and outcomes differ: some studies concern people without diabetes, others type 2 diabetes or particular obesity-related conditions. Results should be interpreted within the relevant trial.
Manufacturer announcements are useful for tracking development, but they should be distinguished from full peer-reviewed reports. A headline percentage does not explain treatment discontinuation, missing data, adverse events or which analysis was used. This page does not rank retatrutide against other medicines using separate trials.
What remains uncertain?
Weight loss or improved HbA1c does not by itself prove fewer heart attacks, longer survival or preserved muscle. Studies designed to assess longer-term cardiovascular and kidney outcomes matter. A positive result in one population should not be assumed to apply to everyone with diabetes.
Regulatory review also assesses benefits, harms, manufacturing and the proposed use of a medicine. Clinical development, approval, local availability and an individual treatment decision are separate steps. An announced trial result is not an approval date or a treatment recommendation.
Safety and products sold online
The FDA states that retatrutide is not a component of an FDA-approved drug and warns against products sold to consumers under “research” labels. Such products may have uncertain ingredients, strength or quality. Trial dosing is not a self-treatment guide, and an online seller’s certificate is not regulatory approval.
If you want help with weight or glucose management, discuss currently approved options with your clinician. Do not replace prescribed treatment with an unapproved product. If interested in research, ask about a registered trial and its eligibility, consent and monitoring arrangements.
Questions worth asking
- Was this result from a peer-reviewed study or a company announcement?
- Did participants have diabetes, and how similar were they to me?
- What were the adverse effects and treatment discontinuations?
- Is this medicine approved locally for the proposed use?
Explore our medication guides and insulin resistance overview. This is research education, not prescribing advice.
Sources
- Jastreboff and colleagues: Retatrutide phase 2 obesity trial, NEJM, 2023; DOI: 10.1056/NEJMoa2301972.
- Lilly: Retatrutide development and status, July 2026; manufacturer information.
- FDA: Concerns about unapproved GLP-1 drugs; includes retatrutide.
Content and regulatory-status check updated: 11 September 2026.